Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …

Objectives Nivolumab is now a reference treatment for patients with advanced non-small cell
lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are …

Introduction Despite comprising many cancer diagnoses, few treatments are suitable for
patients with advanced non-small cell lung cancer (aNSCLC). Trials suggest blockade of …

ABSTRACT EVIDENS is an ongoing, prospective, non-interventional study evaluating the
effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials. gov …

Background Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the
standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here …

Background Over recent years, immune checkpoint inhibitors (ICIs) have changed the
clinical management and prognosis for most cancers. However, data on older patients in …

Immune checkpoint inhibitor (ICI) therapy is now in widespread clinical use for the treatment
of lung cancer. Although patients with autoimmune disease and other comorbidities were …

Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown
superior survival outcomes and improved adverse effects compared to standard …

Abstract Background Patients with Eastern Cooperative Oncology Group Performance
Status 2 (ECOG PS 2) are not included in most randomized clinical trials and registry …

Immunotherapy can reverse tumor immune escape by suppressing immune checkpoints.
Lymphocyte activation gene 3 (LAG3) is an important checkpoint and its role in colorectal …